Stockscreener 앱 받기
11.87
3.32%
0.44
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
CRBP Reiterates by Guggenheim -- Price Target Maintained at $45 - GuruFocus
CRBP: All proposals passed, including annual advisory votes on executive compensation - TradingView
CRBP: All five proposals, including director elections and equity plan amendment, were approved by majority - TradingView
Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating - marketscreener.com
Corbus CEO to outline oncology, obesity pipeline at 2 New York conferences - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.11, Implies 272% Upside - TradingView
Corbus Pharmaceuticals (CRBP) Advances Oncology and Obesity Prog - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Jefferies cuts Corbus Pharmaceuticals stock price target on HNSCC data By Investing.com - Investing.com Canada
[10-Q] Corbus Pharmaceuticals Holdings, Inc. Quarterly Earnings Report - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Stock 12‑Month Price Target Cut to $41.44, Implies 275% Upside - TradingView
Corbus Pharmaceuticals Reports Q1 2026 Results: Advances in CRB-701 for Cancer and CRB-913 for Obesity, FDA Alignment, and Upcoming ASCO Data - Minichart
Corbus Pharmaceuticals Holdings, Inc. posts 2026 first quarter financial results and corporate update - Traders Union
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook - TipRanks
Corbus Pharmaceuticals Releases First Quarter 2026 Financial Results and Corporate Update - geneonline.com
Corbus Pharmaceuticals 1Q Loss/Shr $1.23 >CRBP - Moomoo
Corbus (NASDAQ: CRBP) details Q1 loss, FDA alignment and obesity trial - Stock Titan
Corbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 Programs - Quiver Quantitative
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals: Q1 Earnings Snapshot - marketscreener.com
Obesity and cancer drug trials hit key 2026 milestones at Corbus - Stock Titan
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals in Norwood - Boston Real Estate Times
Avoiding Lag: Real-Time Signals in (CRBP) Movement - Stock Traders Daily
Colliers Facilitates Lease Renewal for Corbus Pharmaceuticals at 500 River Ridge Drive in Norwood - Colliers
Corbus Pharmaceuticals Holdings to unveil new CRB-701 clinical results at ASCO annual meeting - Traders Union
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel - Stock Titan
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
MSN Money - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim - MarketBeat
CRBP Stock Price, Quote & Chart | CORBUS PHARMACEUTICALS HOLDI (NASDAQ:CRBP) - ChartMill
Guggenheim initiates coverage of Corbus Pharmaceuticals Holdings (CRBP) with buy recommendation - MSN
Corbus reaches FDA agreement on development path for cancer drug CRB-701 - MSN
CRBP Initiates Coverage On Guggenheim -- Rating Set to Buy - GuruFocus
Guggenheim Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $45 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus offers upside despite post-FDA update, analyst highlights competitive edge - MSN
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Corporate presentation Summary - Quartr
Corbus Pharmaceuticals (CRBP) Q4 2025 earnings summary - Quartr
Corbus Pharmaceuticals (CRBP) Registration Filing Summary - Quartr
Corbus Pharmaceuticals (CRBP) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary - Quartr
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 - The Manila Times
0.48%
0.62%
자본화:
|
볼륨(24시간):